Takahiro Horie et al. reported that the inhibition of ErbB4 may be one of the reasons why those patients who receive concurrent Dox and trastuzumab therapy suffer from congestive heart failure (CHF). The gene discussed is ERBB4; the disease is congestive heart failure.